Brazil steps up efforts against TB



Brazil’s Ministry of Health (MoH) this week announced that an effervescent tablet that combines all drugs needed for the treatment of tuberculosis (TB) will be adopted in 2020. The product will include a rifampin + isoniazid + pyrazinamide combination for the intensive phase, and rifampin + isoniazid for the maintenance phase. It is designed to improve treatment adherence, especially in children.

The announcement comes as the MoH readies to preside the three following years over the United Nations (UN)’s Stop TB Partnership, which encompasses almost 1,700 institutions in over 100 nations, and aims at eliminating the disease worldwide. At the same time, Brazil will head the BRICS group’s Tuberculosis Research Network, where the country has committed to invest BRL 16 million (USD 3.9 million) in the promotion of new therapies, diagnosis methods, and treatment access.

Reference:

Related news
A multinational research team from African, American and Asian countries, including Brazil, Haiti and Peru, has shown the non-inferiority of a rifapentine + isoniazid treatment that is shorter than the isoniazid monotherapy recommended by the World Health Organization (WHO) for preventing tuberculosis (TB) infections in HIV carriers.
  • 1561111561862
  • Brazil,Peru,Haiti
  • Drug
Brazil’s Institute of Technology and Pharmaceuticals (Farmanguinhos) of the Oswaldo Cruz Foundation (Fiocruz) released 192 drug batches for the Unified Health System (SUS) during Q1’19, totalling 26 million units.
Scientists at Mexico’s Autonomous University of Nuevo Leon (UANL) and the Biotechnology and Nanotechnology Research Center (CIByN) have developed a method to boost the antibiotic effect of conventional tuberculosis (TB) drugs.
China's Tariff Commission of the State Council (TCSC) released a notification in relation to another tariffs levy on imported commodities from the United States, a tit-for-tat step amid the escalating trade war between the two countries.
The China National Drug Administration (CNDA) released a notification on in-human bioequivalency (BE) test requirements for products being put through generics consistency evaluation (GCE).
Recent news
A study carried out by investigators at Brazil’s Oswaldo Cruz Foundation (Fiocruz) estimated the coping costs for the caretakers of minors with one of three selected rare diseases.
Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT) this week ruled that all medical products that contain active pharmaceutical ingredients (APIs) that require bioequivalence tests must submit applications for these studies within 180 days.
Austria-based Themis is set to carry out a Phase III clinical trial (CT) on its chikungunya vaccine candidate.
  • 1568979876836
  • Mexico,Colombia,Guatemala,Dominican Republic,Chile,Puerto Rico ,Nicaragua,Guyana,Brazil,Cuba,Belize,Argentina,Paraguay,Ecuador ,Costa Rica,Peru,El Salvador,Panama,Haiti,Uruguay,Venezuela,Bolivia ,Honduras
  • Drug, Company
China’s leading plasma-based biopharmaceutical company China Biologic Products Holdings Inc., (NASDAQ: CBPO) is once again being targeted by a consortium of investors in a potential USD 4.59 billion buyout deal that would take the firm private.
Suzhou-based biotech CStone Pharmaceuticals (HKEX.2616) announced that the GEMSTONE-101 cohort study for anti-programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb) CS1001 combined with cisplatin plus fluorouracil (CF) therapy in esophagus squamous cell carcinoma (ESCC) has yielded a 77.8% objective response rate (ORR) with good safety.
Shenzhen Chipscreen Biosciences Co., Ltd, (SH.688321) announced acceptance for review from the National Medical Products Administration (NMPA) in relation to a new drug application (NDA) filed for hypoglycemic drug chiglitazar (Bilessglu).
A draft law presented this week to Peru’s unicameral Congress by the New Peru (Nuevo Perú) minority party would force medics to prescribe generic medicines as a primary choice and originator drugs as a second alternative.
Analytics Snapshot